Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma

Inclusion Criteria

• •Patients fully understand the study, voluntarily participate in and sign on the informed consent;
• •Diagnosed by histopathology Peripheral T-cell lymphoma;
• •ECOG PS score 0 or 1;
• •Relapsed or Refractory Peripheral T Cell Lymphoma；
• •According to the 2014 version of the Lugano criteria for lymphoma, there must be at least one CT/MRI measurable lesion (measurable lymph node diameter\>1.5cm; measurable extranodal lesion diameter\>1.0cm)；
• •Provided a written pathological/histological diagnosis report during the screening period and agreed to provide tumor tissue sections or tumor/lymph node tissue specimens for testing at the central laboratory;
• •Expected survival at least 12 weeks；
• •Agreed to receive treatment with Pralatrexate